The primary goal of PIONEER 6 was to compare the time to the first major adverse cardiovascular event between oral semaglutide and placebo
Semaglutide as a Cardiovascular Disease Modifier: Semaglutide belongs to the class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have been found to offer cardioprotective effects beyond glycemic control
Semaglutide, sold under the name Ozempic, Vegovy or Rybelsus, belongs to the pharmacological class of GLP-1 (glucagon-like peptide-1) analogues, which work by mimicking the natural hormones called incretins, responsible for initiating insulin production after meal as well as reducing appetite and slowing the food digestion
But Azar said she's seen patients maintain some weight loss as long as they stick to healthy lifestyle changes such as moving their body throughout the day, eating whole foods and prioritizing protein in their diet.
A minimum of 12 weeks at the maintenance dose of 2.4 mg is generally recommended before determining whether the medication is working optimally for weight loss
But it does mean the risk profile is fundamentally different from FDA-approved products, and patients need to take active responsibility for verifying the quality of what they are injecting